Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Longterm therapy and etofibrate (author's transl)].

H Kaffarnik, J Schneider, R Schubotz

    MMW, Munchener Medizinische Wochenschrift
    |January 18, 1980
    PubMed
    Summary

    Etofibrate effectively lowers cholesterol and triglyceride levels in patients with hyperlipoproteinemia. This potent hypolipidemic agent demonstrated good tolerance for long-term use without tachyphylaxis.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Metabolic basis of high density lipoproteins and apolipoprotein A-I increase by HMG-CoA reductase inhibition in healthy subjects and a patient with coronary artery disease.

    Atherosclerosis·1999
    Same author

    [Alcohol, lipid metabolism and coronary heart disease].

    Herz·1996
    Same author

    Multicenter comparison of micronized fenofibrate and simvastatin in patients with primary type IIA or IIB hyperlipoproteinemia.

    Journal of cardiovascular pharmacology·1996
    Same author

    [Oral contraceptive-induced pancreatitis in the hyperchylomicronemia syndrome].

    Deutsche medizinische Wochenschrift (1946)·1995
    Same author

    Influence of somatostatin to biochemical parameters in patients with primary hyperparathyroidism.

    Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association·1995
    Same author

    [Adrenomyeloneuropathy. A frequent cause of Addison's disease].

    Deutsche medizinische Wochenschrift (1946)·1994

    Area of Science:

    • Cardiology
    • Pharmacology

    Context:

    • Hyperlipoproteinemia presents challenges in patient stabilization.
    • Routine care parameters often require differentiation for effective management.

    Purpose:

    • To evaluate the efficacy and tolerance of etofibrate in difficult-to-stabilize hyperlipoproteinemic patients.
    • To assess the impact of etofibrate on cholesterol, triglyceride, and other laboratory parameters.

    Summary:

    • Twenty patients with hyperlipoproteinemia (types IIa, IIb, IV) received 0.9 g of etofibrate daily.
    • Treatment resulted in an 18% reduction in cholesterol and a 50% reduction in triglycerides.
    • No tachyphylaxis was observed, and the drug was well-tolerated.

    Impact:

    • Etofibrate is a potent hypolipidemic agent suitable for long-term hyperlipoproteinemia management.
    • Demonstrates significant lipid-lowering effects and good patient tolerance.

    Related Experiment Videos